Abeona Q2 2026: ZEVASKYN Revenue Grows 31% to $11.4M, Cash Runway Extended
ABEO sits 90% above its 52-week low of $4.
Summary
Abeona reported Q2 2026 revenue of $11.4 million, up 31% sequentially, with $146.8 million in cash. The filing also disclosed a manufacturing batch rejection and a non-cash warrant liability increase.
Key Events · Earnings and Guidance · ABEO
-
ZEVASKYN Revenue Growth
Q2 2026 product revenue of $11.4 million, up 31% from Q1 2026, driven by ZEVASKYN launch progress.
-
Cash Runway
Cash resources of $146.8 million as of June 30, 2026, sufficient to fund operations for at least the next 12 months.
-
Manufacturing Batch Rejection
A July 2026 ZEVASKYN batch could not be released commercially due to a cellular identity test out of specification; FDA authorized release under a single-patient IND.
-
Warrant Liability Increase
Warrant liabilities increased to $20.7 million from $18.9 million, a non-cash charge driven by the higher share price.
Analysis · ABEO · Life Sciences
Abeona's Q2 2026 10-Q shows ZEVASKYN revenue of $11.4 million, up 31% from Q1, with $146.8 million in cash resources providing runway through at least the next 12 months. The filing also discloses a manufacturing batch rejection in July 2026 due to a cellular identity test out of specification, which could impact near-term supply. The warrant liability increased to $20.7 million due to the rising stock price, a non-cash charge. The company has $51.5 million remaining under its ATM facility.
How filings like this one have moved
In the 30 days to Oct 31, 2026, 31.5% of the 1750 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ABEO was trading at $7.60 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $425.2M. The 52-week trading range was $4.00 to $7.65. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.